Cytarabine Drug Asset Due Diligence Report 2026

This Cytarabine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

1450

Registered trials

802

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cytarabine can convert its Small molecule drug profile and DNA-directed DNA polymerase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cytarabine (query alias: cytarabine)
Modality / target	Small molecule drug; DNA-directed DNA polymerase; DNA-directed DNA polymerase inhibitors, DNA synthesis inhibitors
Highest global status	Approved
Originator	Teva Pharmaceutical Industries Ltd.
Active developers	Nippon Shinyaku Co., Ltd., Amgen, Inc., Takeda Pharmaceutical Co., Ltd.

The MCP disease footprint includes Meningeal Leukemia, Non-Hodgkin Lymphoma, Blast Phase Chronic Granulocytic Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600127203	Phase 2	Not yet recruiting	55	Composite Complete Remission Rate
NCT07651475	Phase 2	Active, not recruiting	32	Composite Complete Remission Rate (CRc)
NCT07686107	Phase 2	Not yet recruiting	24	Best Overall Response Rate (BOR) by morphologic response criteria

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Adjuvant (Ad) and neoadjuvant (NAd) strategies in higher risk hormone receptor–positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC): Moroccan real-world outcomes.

Not Applicable; n=660; evaluation: Positive. Reported fields: mDFS = NE Month ( 17 - NE); mDFS = 44.0 Month ( 26 - NE)

Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

Not Applicable; n=280; evaluation: Positive. Reported fields: Early infectious complications(within 30 days) = 58.6 % ; Early infectious complications(within 30 days) = 53.2 %

Treatment outcomes and unmet needs in patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC): A systematic literature review (SLR).

Not Applicable; n=55; evaluation: Positive. Reported fields: CR = 25.0 % ( 17 - 35); -; CR = 10.0 % ( 4 - 25)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cytarabine addresses Meningeal Leukemia, Non-Hodgkin Lymphoma, Blast Phase Chronic Granulocytic Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2010-01-29	Enzon Pharmaceuticals, Inc. announced today that it has closed the sale of its specialty pharmaceutical business to the sigma-tau Group	Approved	US$300.0M upfront; US$27.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Cytarabine-amino acid based prodrug for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Use of pharmaceutical composition comprising mitoxantrone liposome and cytarabine in the treatment of acute myeloid leukemia”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO